

Original Publications – C Christofer Juhlin as of September 2nd 2020

1. Allelic loss in clinically and screening-detected primary hyperparathyroidism.
Correa P, Juhlin C, Rastad J, Åkerström G, Westin G, Carling T.
Clin Endocrinol (Oxf). 2002 Jan;56(1):113-7.
PMID: 11849254
2. Loss of parafibromin expression in a subset of parathyroid adenomas.
Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, Alimov A, Weber G, Höög A, Villablanca A.
Endocr Relat Cancer. 2006 Jun;13(2):509-23.
PMID: 16728578
3. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenström J, Forsberg L, Bränström R, Obara T, Arnold A, Larsson C, Höög A.
Endocr Relat Cancer. 2007 Jun;14(2):501-12.
PMID: 17639063
4. Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma.
Geli J, Kogner P, Lanner F, Natalishvili N, Juhlin C, Kiss N, Clark GJ, Ekström TJ, Farnebo F, Larsson C.
Int J Cancer. 2008 Jul 15;123(2):389-94. doi: 10.1002/ijc.23533.
PMID: 18452173
5. Heterogeneous expression of SNARE proteins SNAP-23, SNAP-25, Syntaxin1 and VAMP in human parathyroid tissue.
Lu M, Forsberg L, Höög A, Juhlin CC, Vukojević V, Larsson C, Conigrave AD, Delbridge LW, Gill A, Bark C, Farnebo LO, Bränström R.
Mol Cell Endocrinol. 2008 Jun 11;287(1-2):72-80. doi: 10.1016/j.mce.2008.01.028.
PMID: 18457912
6. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas.
Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Bränström R, Larsson C, Höög A.
Int J Oncol. 2009 Feb;34(2):481-92.
PMID: 19148484
7. Transcriptional profiling enables molecular classification of adrenocortical tumours.
Laurell C, Velázquez-Fernández D, Lindsten K, Juhlin C, Enberg U, Geli J, Höög A, Kjellman M, Lundeberg J, Hamberger B, Larsson C, Nilsson P, Bäckdahl M.
Eur J Endocrinol. 2009 Jul;161(1):141-52. doi: 10.1530/EJE-09-0068.
PMID: 19411298
8. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.
Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, Larsson C.
PLoS One. 2010 Mar 1;5(3):e9472. doi: 10.1371/journal.pone.0009472.
PMID: 20208994
9. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C.
Endocr Pathol. 2010 Sep;21(3):166-77. doi: 10.1007/s12022-010-9121-z. (*)

PMID: 20473645

10. Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca²⁺-binding protein S100A6 in papillary thyroid carcinoma.
Sofiadis A, Dinets A, Orre LM, Branca RM, Juhlin CC, Foukakis T, Wallin G, Höög A, Hulchiy M, Zedenius J, Larsson C, Lehtiö J.
Thyroid. 2010 Oct;20(10):1067-76. doi: 10.1089/thy.2009.0400.
PMID: 20629554
11. Lack of S37A CTNNB1/ β -catenin mutations in a Swedish cohort of 98 parathyroid adenomas.
Haglund F, Andreasson A, Nilsson IL, Höög A, Larsson C, Juhlin CC.
Clin Endocrinol (Oxf). 2010 Oct;73(4):552-3. doi: 10.1111/j.1365-2265.2010.03830.x.
PMID: 20550535
12. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
Juhlin CC, Haglund F, Obara T, Arnold A, Larsson C, Höög A.
Virchows Arch. 2011 Jul;459(1):47-53. doi: 10.1007/s00428-010-1032-3.
PMID: 21221636
13. Parathyroid carcinoma arising from four-gland hyperplasia.
Kauffmann RM, Juhlin CC, Fohn LE, Broome JT, Phay JE.
Endocr Pract. 2011 Mar-Apr;17(2):e37-42. doi: 10.4158/EP10211.CR.
PMID: 21247853
14. Molecular characterization of parathyroid tumors from two patients with hereditary colorectal cancer syndromes.
Andreasson A, Sulaiman L, do Vale S, Martins JM, Ferreira F, Miltenberger-Miltenyi G, Batista L, Haglund F, Björck E, Nilsson IL, Höög A, Larsson C, Juhlin CC.
Fam Cancer. 2012 Sep;11(3):355-62. doi: 10.1007/s10689-012-9520-z.
PMID: 22395475
15. Genetic characterization of large parathyroid adenomas.
Sulaiman L, Nilsson IL, Juhlin CC, Haglund F, Höög A, Larsson C, Hashemi J.
Endocr Relat Cancer. 2012 May 24;19(3):389-407. doi: 10.1530/ERC-11-0140.
PMID: 22454399
16. Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.
Haglund F, Lu M, Vukojević V, Nilsson IL, Andreasson A, Džabić M, Bränström R, Höög A, Juhlin CC, Larsson C.
PLoS One. 2012;7(5):e36448. doi: 10.1371/journal.pone.0036448.
PMID: 22606260
17. Evidence of a functional estrogen receptor in parathyroid adenomas.
Haglund F, Ma R, Huss M, Sulaiman L, Lu M, Nilsson IL, Höög A, Juhlin CC, Hartman J, Larsson C.
J Clin Endocrinol Metab. 2012 Dec;97(12):4631-9. doi: 10.1210/jc.2012-2484.
PMID: 23024189
18. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
Sulaiman L, Haglund F, Hashemi J, Obara T, Nordenström J, Larsson C, Juhlin CC.
PLoS One. 2012;7(9):e46325. doi: 10.1371/journal.pone.0046325.
PMID: 23029479

19. Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation.
Kiss NB, Muth A, Andreasson A, Juhlin CC, Geli J, Bäckdahl M, Höög A, Wängberg B, Nilsson O, Ahlman H, Larsson C.
Endocr Relat Cancer. 2013 Feb 18;20(1):65-78. doi: 10.1530/ERC-12-0267.
PMID: 23154831

20. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
Andreasson A, Kiss NB, Caramuta S, Sulaiman L, Svahn F, Bäckdahl M, Höög A, Juhlin CC, Larsson C.
Epigenetics. 2013 Dec;8(12):1347-54. doi: 10.4161/epi.26686.
PMID: 24149047

21. Global and gene-specific promoter methylation analysis in primary hyperparathyroidism.
Sulaiman L, Juhlin CC, Nilsson IL, Fotouhi O, Larsson C, Hashemi J.
Epigenetics. 2013 Jun;8(6):646-55. doi: 10.4161/epi.24823.
PMID: 23764768

22. Long-term storage of endocrine tissues at - 80°C does not adversely affect RNA quality or overall histomorphology.
Andreasson A, Kiss NB, Juhlin CC, Höög A.
Biopreserv Biobank. 2013 Dec;11(6):366-70.
PMID: 24475321

23. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma.
Welander J*, Andreasson A*, Juhlin CC, Wiseman RW, Bäckdahl M, Höög A, Larsson C, Gimm O, Söderkvist P.
J Clin Endocrinol Metab. 2014 Jul;99(7):E1352-60. doi: 10.1210/jc.2013-4375.
*Shared first authorship
PMID: 24694336

24. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Bäckdahl M, Healy JM, Prasad ML, Korah R, Carling T, Xu D, Larsson C.
Endocr Relat Cancer. 2014 May 6;21(3):427-34. doi: 10.1530/ERC-14-00
PMID: 24803525

25. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Höög A, Larsson C, Xu D.
Cancer. 2014 Oct 1;120(19):2965-79. doi: 10.1002/cncr.28800.
PMID: 24898513

26. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.
Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminsky VO, Juhlin CC, Höög A, Bodin I, Svjatoha V, Larsson C, Zedenius J, Wennerberg J, Lundqvist A.
Clin Cancer Res. 2014 Nov 15;20(22):5733-44. doi: 10.1158/1078-0432.CCR-14-0291.
PMID: 25212604

27. Frequent Silencing of RASSF1A via Promoter Methylation in Follicular Thyroid Hyperplasia: A Potential Early Epigenetic Susceptibility Event in Thyroid Carcinogenesis.
Brown TC, Juhlin CC, Healy JM, Prasad ML, Korah R, Carling T.
JAMA Surg. 2014 Nov 1;149(11):1146-52. doi: 10.1001/jamasurg.2014.1694.
PMID: 25229773

28. Soluble tumor necrosis factor receptor 1 (sTNFR1) is associated with increased total mortality due to cancer and cardiovascular causes - Findings from two community based cohorts of elderly.
Carlsson AC, Juhlin CC, Larsson TE, Larsson A, Ingelsson E, Sundström J, Lind L, Arnlöv J.
Atherosclerosis. 2014 Nov;237(1):236-42. doi:10.1016/j.atherosclerosis.2014.09.005.
PMID: 25255422

29. Immunohistochemical NF1 Analysis Does not Predict NF1 Gene Mutation Status in Pheochromocytoma.
Stenman A, Svahn F, Welander J, Gustavson B, Söderkvist P, Gimm O, Juhlin CC.
Endocr Pathol. 2015 Mar;26(1):9-14. doi: 10.1007/s12022-014-9348-1.
PMID: 25403449

30. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
Juhlin CC*, Goh G*, Healy JM*, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp A, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T.
J Clin Endocrinol Metab. 2015 Mar;100(3):E493-502. doi: 10.1210/jc.2014-3282.
*Shared first authorship
PMID: 25490274

31. Characterization of the mutational landscape of anaplastic thyroid cancer via whole exome sequencing.
Kunstman JW*, Juhlin CC*, Goh G*, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, Höög A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T.
Hum. Mol. Genet. 2015 Apr 15;24(8):2318-29. doi: 10.1093/hmg/ddu749.
*Shared first authorship
PMID: 25576899

32. Tumour nuclear oestrogen receptor beta 1 correlates inversely to parathyroid tumour weight.
Haglund F, Rosin G, Nilsson IL, Juhlin CC, Pernow Y, Norenstedt S, Dinets A, Larsson C, Hartman J, Höög A.
Endocr Connect. 2015 Mar;4(1):76-85. doi: 10.1530/EC-14-0109.
PMID: 25648860

33. TERT promoter mutations are rare in parathyroid tumors.
Haglund F*, Juhlin CC*, Brown T, Ghaderi M, Liu T, Stenman A, Dinets A, Prasad M, Korah R, Xu D, Carling T, Larsson C.
Endocr Relat Cancer. 2015 Jun;22(3):L9-L11. doi: 10.1530/ERC-15-0121.
*Shared first authorship
PMID: 25876648

34. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism.
Scholl UI, Stölting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP.
Elife. 2015 Apr 24;4:e06315. doi: 10.7554/eLife.06315.
PMID: 25907736

35. Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions.
Dinets A, Pernemalm M, Kjellin H, Sviatoha V, Sofiadis A, Juhlin CC, Zedenius J, Larsson C, Lehtiö J, Höög A.
PLoS One. 2015 May 15;10(5):e0126472. doi: 10.1371/journal.pone.0126472.
PMID: 25978681

36. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene.
Juhlin CC, Stenman A, Haglund F, Clark VE, Brown TC, Baranoski J, Bilguvar K, Goh G, Welander J, Svahn F, Rubinstein JC, Caramuta S, Yasuno K, Günel M, Bäckdahl M, Gimm O, Söderkvist P, Prasad ML, Korah R, Lifton RP, Carling T.
Genes Chromosomes Cancer. 2015 Sep;54(9):542-54. doi: 10.1002/gcc.22267.
PMID: 26032282

37. Absence of KMT2D/MLL2 mutations in abdominal paraganglioma.
Stenman A*, Juhlin CC*, Haglund F, Brown TC, Clark VE, Svahn F, Bilguvar K, Goh G, Korah R, Lifton RP, Carling T.
Clin Endocrinol (Oxf). 2015 Aug 25. doi: 10.1111/cen.12884. [Epub ahead of print]
*Shared first authorship
PMID: 26303934

38. Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma.
Rubinstein JC, Brown TC, Goh G, Juhlin CC, Stenman A, Korah R, Carling T.
Surgery. 2015 Oct 6. pii: S0039-6060(15)00720-5. doi: 10.1016/j.surg.2015.09.001.
PMID: 26453132

39. DNA Copy Amplification and Overexpression of SLC12A7 in Adrenocortical Carcinoma.
Brown TC, Juhlin CC, Healy JM, Stenman A, Rubinstein JC, Korah R, Carling T.
Surgery. 2015 Oct 7. pii: S0039-6060(15)00734-5.
PMID: 26454676

40. Absence of BRAFV600E mutation in adrenal tumors.
Paulsson JO, Svahn F, Welander J, Brunaud L, Söderkvist P, Gimm O, Stenman A, Juhlin CC.
J Endocrinol Invest. 2015 Dec 28. [Epub ahead of print]
PMID: 26710756

41. Soft Tissue Metastasis of Parathyroid Carcinoma: Description of a Difficult Case. Martins AF, Martins JM, do Vale C, Juhlin CC, Batista L, Franco M, Lopez-Presa D, Miltenberger-Miltenyi G.
J Endocrinol Metab. 2015; 5, 184-188. Not yet indexed in PubMed.
42. *HRAS* mutation prevalence and associated expression patterns in non-familial pheochromocytoma.
Stenman A, Welander J, Gustavsson I, Brunaud L, Bäckdahl M, Söderkvist P, Gimm O, Juhlin CC, Larsson C.
Genes Chromosomes Cancer. 2016 Jan 16. doi: 10.1002/gcc.22347. [Epub ahead of print]
PMID: 26773571
43. Minimally invasive follicular thyroid carcinomas: prognostic factors.
Stenson G, Nilsson IL, Mu N, Larsson C, Lundgren CI, Juhlin CC, Höög A, Zedenius J.
Endocrine. 2016 Feb 8. [Epub ahead of print]
PMID: 26858184
44. Diffuse PTH expression in parathyroid tumors argues against important functional tumor subclones.
Haglund F, Juhlin CC, Kiss NB, Larsson C, Nilsson IL, Höög A.
Eur J Endocrinol. 2016 2016 May;174(5):583-90. doi: 10.1530/EJE-15-1062
PMID: 26865585
45. Genetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
Wang N, Kjellin H, Sofiadis A, Fotouhi O, Juhlin CC, Bäckdahl M, Zedenius J, Xu D, Lehtiö J, Larsson C.
Oncotarget. 2016 Feb 8. doi: 10.18632/oncotarget.7237. [Epub ahead of print]
PMID: 26870890
46. Detailed lymph node sectioning of papillary thyroid carcinoma specimen increases the number of pN1a patients.
Haglund F, Garvin S, Ihre-Lundgren C, Nilsson IL, Hall E, Carling T, Höög A, Juhlin CC.
Endocr Pathol. 2016 Jun 1. [Epub ahead of print]
PMID: 27251056
47. Proteomics suggests a role for APC-survivin in response to somatostatin analog treatment of neuroendocrine tumors.
Fotouhi O, Kjellin H, Larsson C, Hashemi J, Barriuso J, Juhlin CC, Lu M, Höög A, Pastríán LG, Lamarca A, Soto VH, Zedenius J, Mendiola M, Lehtiö J, Kjellman M.
J Clin Endocrinol Metab. 2016 Jul 26;jc20162028. [Epub ahead of print]
PMID: 27459532
48. Shifting patterns of genomic variation in the somatic evolution of papillary thyroid carcinoma.
Rubinstein JC, Brown TC, Christison-Lagay ER, Zhang Y, Kunstman JW, Juhlin CC, Nelson-Williams C, Goh G, Quinn CE, Callender GG, Udelsman R, Lifton RP, Korah R, Carling T.

- BMC Cancer*. 2016 Aug 18;16:646. doi: 10.1186/s12885-016-2665-7.
49. Human cytochrome P450 2W1 is not expressed in adrenal cortex and is only rarely expressed in adrenocortical carcinomas.
Nolé P, Duijndam B, Stenman A, Juhlin CC, Kozyra M, Larsson C, Ingelman-Sundberg M, Johansson I.
PLoS One. 2016 Sep 6;11(9):e0162379. doi: 10.1371/journal.pone.0162379. eCollection 2016.
PMID: 27598485
 50. Loss of miR-514a-3p regulation of PEG3 activates the NF-kappa B pathway in human testicular germ cell tumors.
DM Özata, X Li, L Lee, J Liu, D Warsito, P Hajeri, I Hultman, O Fotouhi, S Marklund, L Åhrlund-Richter, CC Juhlin, C Larsson and W-O Lui.
Cell Death Dis. 2017 May 4;8(5):e2759. doi: 10.1038/cddis.2016.464.
PMID: 28471449
 51. Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma. Murtha TD, Brown TC, Rubinstein JC, Haglund F, Juhlin CC, Larsson C, Korah R, Carling T.
Surgery. 2017 Jun;161(6):1667-1674. doi: 10.1016/j.surg.2016.11.036. Epub 2017 Jan 7. PMID: 28073588
 52. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
Cheng JY, Brown TC, Murtha TD, Stenman A, Juhlin CC, Larsson C, Healy JM, Prasad ML, Knoefel WT, Krieg A, Scholl UI, Korah R, Carling T.
BMC Cancer. 2017 Mar 1;17(1):164. doi: 10.1186/s12885-017-3152-5.
PMID: 28249601
 53. Inflammatory Infiltrates in Parathyroid Tumors.
Haglund F, Hallström B, Nilsson IL, Höög A, Juhlin CC, Larsson C.
Eur J Endocrinol. 2017 Dec;177(6):445-453. doi: 10.1530/EJE-17-0277. Epub 2017 Aug 30. PMID: 28855268
 54. Lymphocytic adrenal medullitis: case report of a patient with pheochromocytoma-like hypertensive paroxysms.
Calissendorff J, Juhlin CC.
ECED Reports. Accepted manuscript, October 2017. Not yet indexed in PubMed.
 55. TERT promoter hypermethylation is associated with metastatic disease in abdominal paraganglioma.
Svahn F, Juhlin CC, Paulsson JO, Fotouhi O, Zedenius J, Larsson C, Stenman A.
Clin Endocrinol (Oxf). 2018 Feb;88(2):343-345. doi: 10.1111/cen.13513. Epub 2017 Nov 27. No abstract available.
PMID: 29130501

56. Riedels thyroiditis: clinical presentation, treatment and outcomes.
Falhammar H, Juhlin CC, Barner C, Catrina SB, Karefylakis C, Calissendorff J.
Endocrine. 2018 Apr;60(1):185-192. doi: 10.1007/s12020-018-1526-3. Epub 2018 Jan 29. PMID:29380231

57. Somatostatin Receptor Expression in Renal Cell Carcinoma-A New Front in the Diagnostics and Treatment of Renal Cell Carcinoma.
Höög A, Kjellman M, Mattsson P, Juhlin CC, Shabo I.
Clin Genitourin Cancer. 2018 Jun;16(3):e517-e520. doi: 10.1016/j.clgc.2018.03.011. Epub 2018 Mar 27. No abstract
PMID: 29656940

58. TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours.
Paulsson JO, Mu N, Shabo I, Wang N, Zedenius J, Larsson C, Juhlin CC.
Endocr Relat Cancer. 2018 Jul;25(7):723-733. doi: 10.1530/ERC-18-0050. Epub 2018 Apr 24. PMID: 29692346

59. Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology.
Nicolson NG, Murtha TD, Dong W, Paulsson JO, Choi J, Barbieri AL, Brown TC, Kunstman JW, Larsson C, Prasad ML, Korah R, Lifton RP, Juhlin CC, Carling T.
J Clin Endocrinol Metab. 2018 Jul 1;103(7):2640-2650. doi: 10.1210/jc.2018-00277. PMID: 29726952

60. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
Stenman A, Zedenius J, Juhlin CC.
Langenbecks Arch Surg. 2018 Sep;403(6):785-790. doi: 10.1007/s00423-018-1679-9. Epub 2018 May 19.
PMID: 29779047

61. High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma.
Mu N, Juhlin CC, Tani E, Sofiadis A, Reihner E, Zedenius J, Larsson C, Nilsson IL.
Endocrine. 2018 Aug;61(2):293-302. doi: 10.1007/s12020-018-1627-z. Epub 2018 May 23. PMID: 29796987

62. Extensive Bilateral Adrenal Rest Testicular Tumors in a Patient With 3 β -Hydroxysteroid Dehydrogenase Type 2 Deficiency.
Lolis E, Juhlin CC, Nordenström A, Falhammar H.
J Endocr Soc. 2018 May 1;2(6):513-517. doi: 10.1210/js.2018-00082. eCollection 2018 Jun 1. PMID: 29850650

63. TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumours - three examples from the clinical routine.

- Hysek M, Paulsson JO, Wang N, Jatta K, Lindh C, Fuentes-Martinez N, Shabo I, Zedenius J, Juhlin CC.
Virchows Arch. 2018 Nov;473(5):639-643. doi: 10.1007/s00428-018-2386-1. Epub 2018 Jun 2. PMID: 29860621
64. Papillary thyroid carcinoma with pleomorphic tumor giant cells in a pregnant woman - a case report.
Paulsson JO, Zedenius J, Juhlin CC.
BMC Endocr Disord. 2018 Jul 5;18(1):46. doi: 10.1186/s12902-018-0275-x. PMID: 29976183
65. Solid Cell Nests Within a Parathyroid Gland - Report of an Exceptional Case.
Juhlin CC, Nilsson IL, Höög A.
Endocr Pathol. 2018 Dec;29(4):365-368. doi: 10.1007/s12022-018-9539-2. PMID: 30003532
66. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F, Paulsson JO, Stenman A, Fotouhi O, Mu N, Murtha TD, Korah R, Carling T, Bäckdahl M, Wang N, Juhlin CC, Larsson C.
Int J Mol Med. 2018 Sep;42(3):1675-1683. doi: 10.3892/ijmm.2018.3735. Epub 2018 Jun 20. PMID: 29956721
67. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Yuan X, Mu N, Wang N, Strååt K, Sofiadis A, Guo Y, Stenman A, Li K, Cheng G, Zhang L, Kong F, Ekblad L, Wennerberg J, Nilsson IL, Juhlin CC, Larsson C, Xu D.
Oncogene. 2019 Feb;38(7):965-979. doi: 10.1038/s41388-018-0483-x. Epub 2018 Sep 4. PMID: 30181547
68. TERT immunohistochemistry is a poor predictor of TERT promoter mutations and gene expression in follicular thyroid carcinoma.
Paulsson JO, Olander A, Haglund F, Zedenius J and Juhlin CC.
Endocr Pathol. 2018 Dec;29(4):380-383. doi: 10.1007/s12022-018-9551-6. PMID: 30306386
69. Clear cell variant of a follicular thyroid tumor with uncertain malignant potential – a case report.
Juhlin CC, Bränström R, Shabo I and Höög A.
Int J Surg Pathol. 2018. 2019 May;27(3):290-293. doi: 10.1177/1066896918809490. Epub 2018 Oct 29. PMID: 30370813
70. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.

Stenman A, Svahn F, Hojjat-Farsangi M, Zedenius J, Söderkvist P, Gimm O, Larsson C* and Juhlin CC*.

Am J Surg Pathol. 2019 Mar;43(3):409-421. doi: 10.1097/PAS.0000000000001190.

PMID: 30451732

71. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors.
Fotouhi O, Zedenius J, Höög A and Juhlin CC.
Neuroendocrinol Letters. 2018 Oct;39(4):305-309.
PMID: 30531706
72. Impact of immunohistochemistry on the diagnosis and management of primary aldosteronism: An important tool for improved patient follow-up.
Volpe C, Hamberger B, Zedenius J and Juhlin CC.
Scand J Surg. 2019 Jan 17:1457496918822622. doi: 10.1177/1457496918822622.
[Epub ahead of print]
73. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
Juhlin CC, Nilsson IL, Lagerstedt-Robinson K, Stenman A, Bränström R, Tham E, Höög A.
Mod Pathol. 2019 Jul;32(8):1082-1094. doi: 10.1038/s41379-019-0252-6. Epub 2019 Mar 28. PMID: 30923346
74. The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature.
Stenman A, Zedenius J, Juhlin CC.
Cancers (Basel). 2019 Feb 15;11(2). pii: E225. doi: 10.3390/cancers11020225. Review.
75. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case.
Juhlin CC, Höög A.
Int J Surg Pathol. 2019 Sep;27(6):658-663. doi: 10.1177/1066896919837678. Epub 2019 Apr 1.
PMID: 30931661
76. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
Brown TC, Nicolson NG, Stenman A, Juhlin CC, Gibson CE, Callender GG, Korah R, Carling T.
J Am Coll Surg. 2019 Sep;229(3):305-315. doi: 10.1016/j.jamcollsurg.2019.04.018. Epub 2019 Apr 26.
PMID: 31034883

77. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A, Hysek M, Jatta K, Bränström R, Darai-Ramqvist E, Paulsson JO, Wang N, Larsson C, Zedenius J, Juhlin CC.
Endocr Pathol. 2019 Sep;30(3):246-248. doi: 10.1007/s12022-019-09580-7.
PMID: 31154561
78. Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple autophagy genes.
Kumar S, Xie H, Shi H, Gao J, Juhlin CC, Björnhagen V, Höög A, Lee L, Larsson C, Lui WO.
Int J Cancer. 2019 Jun 10. doi: 10.1002/ijc.32503. [Epub ahead of print]
PMID: 31180579
79. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A, Zedenius J, Juhlin CC.
Surgery. 2019 Jun 22. pii: S0039-6060(19)30241-7. doi: 10.1016/j.surg.2019.04.030.
[Epub ahead of print]
PMID: 31239074
80. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant TERT promoter methylation, but not hot-spot mutations.
Fotouhi O, Ghaderi M, Wang N, Zedenius J, Kjellman M, Xu D, Juhlin CC, Larsson C.
Epigenetics. 2019 Jul 19:1-10. doi: 10.1080/15592294.2019.1634987. [Epub ahead of print] PMID: 31322481
81. EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.
Li S, Rodriguez J, Li W, Bullova P, Fell SM, Surova O, Westerlund I, Topcic D, Bergsland M, Stenman A, Muhr J, Nistér M, Holmberg J, Juhlin CC, Larsson C, von Kriegsheim A, Kaelin WG Jr, Schlisio S.
Proc Natl Acad Sci U S A. 2019 Aug 2. pii: 201900748. doi: 10.1073/pnas.1900748116.
[Epub ahead of print] PMID: 31375625
82. Presentation, Treatment, Histology, and Outcomes in Adrenal Medullary Hyperplasia Compared With Pheochromocytoma.
Falhammar H, Stenman A, Calissendorff J, Juhlin CC.
J Endocr Soc. 2019 Jun 11;3(8):1518-1530. doi: 10.1210/js.2019-00200. eCollection 2019 Aug 1.
PMID: 31384714
83. Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy.

Neumann HPH, Tsoy U, Bancos I, Amodru V, Walz MK, Tirosh A, Kaur RJ, McKenzie T, Qi X, Bandgar T, Petrov R, Yukina MY, Roslyakova A, van der Horst-Schrivers ANA, Berends AMA, Hoff AO, Castroneves LA, Ferrara AM, Rizzati S, Mian C, Dvorakova S, Hasse-Lazar K, Kvachenyuk A, Peczkowska M, Loli P, Erenler F, Krauss T, Almeida MQ, Liu L, Zhu F, Recasens M, Wohlk N, Corssmit EPM, Shafigullina Z, Calissendorff J, Grozinsky-Glasberg S, Kunavisarut T, Schalin-Jäntti C, Castinetti F, Vlcek P, Beltsevich D, Egorov VI, Schiavi F, Links TP, Lechan RM, Bausch B, Young WF Jr, Eng C; International Bilateral-Pheochromocytoma-Registry Group.

JAMA Netw Open. 2019 Aug 2;2(8):e198898. doi: 10.1001/jamanetworkopen.2019.8898.

PMID: 31397861

84. Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors.
Fotouhi O, Kjellin H, Juhlin CC, Pan Y, Vesterlund M, Ghaderi M, Yousef A, Andersson-Sand H, Kharaziha P, Caramuta S, Kjellman M, Zedenius J, Larsson C, Orre LM.
Oncogene. 2019 Aug 12. doi: 10.1038/s41388-019-0938-8. [Epub ahead of print]
PMID: 31406256
85. Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-U MPs): A Useful Predictor of Metastatic Disease.
Hysek M, Paulsson JO, Jatta K, Shabo I, Stenman A, Höög A, Larsson C, Zedenius J, Juhlin CC.
Cancers (Basel). 2019 Sep 26;11(10). pii: E1443. doi: 10.3390/cancers11101443.
86. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation.
Paulsson JO, Backman S, Wang N, Stenman A, Crona J, Thutkawkorapin J, Ghaderi M, Tham E, Ståhlberg P, Zedenius J, Juhlin CC.
J Pathol. 2019 Oct 17. doi: 10.1002/path.5359. [Epub ahead of print]
PMID: 31621921
87. Synchronous aldosterone- and cortisol-producing adrenocortical adenomas diagnosed using CYP11B immunohistochemistry.
Stenman A, Shabo I, Ramström A, Zedenius J, Juhlin CC.
SAGE Open Med Case Rep. 2019 Oct 18;7:2050313X19883770. doi: 10.1177/2050313X19883770. eCollection 2019.
PMID: 31666955 Free PMC Article
88. Signet ring cell variant of follicular thyroid carcinoma: Report of two cases with focus on morphological, expressional and genetic characteristics.
Hysek M, Jatta K, Stenman A, Darai-Ramqvist E, Zedenius J, Höög A, Juhlin CC.
Diagn Pathol. 2019 Nov 7;14(1):127. doi: 10.1186/s13000-019-0904-3.
PMID: 31699114 Free PMC Article

89. A Rare Case of Giant Amyloid Goiter: A Case Report and Review of Literature.
Juhlin CC, Karlsson F, Bränström R.
Medical Case Rep. May 2019. Not yet indexed in PubMed.
90. Non-functioning neuroendocrine pancreatic tumors transforming to malignant insulinomas - four cases and review of the literature.
Juhlin CC, Skoglund S, Juntti-Berggren L, Karlberg M, Calissendorff J.
Neuroendocrinology Letters. 2019 Nov;40(4):175-183.
PMID: 32087093
91. Metastatic anaplastic thyroid carcinoma in complete remission: Morphological, molecular and clinical work-up of a rare case.
Stenman A, Hellgren LS, Jatta K, Hysek M, Zemmler M, Altena R, Nilsson IL, Bränström R, Zedenius J, Juhlin CC.
Endocrine Pathology 2020 Mar;31(1):77-83.
PMID: 32016808
92. Metastatic malignant melanoma with neuroendocrine differentiation – report of a rare case and review of the literature
Juhlin CC, Zedenius J, Haglund F.
J Med Case Rep, In press.
93. GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours.
Paulsson JO, Wang N, Gao J, Stenman A, Zedenius J, Mu N, Lui WO, Larsson C, Juhlin CC.
Endocr Relat Cancer. 2020 Mar 1. pii: ERC-19-0446.R1. doi: 10.1530/ERC-19-0446.
[Epub ahead of print]
PMID: 32163919
94. Lipoadenoma of the Parathyroid Gland: Characterization of an Institutional Series Spanning 28 Years.
Juhlin CC, Falhammar H, Zedenius J, Nilsson IL, Höög A.
Endocr Pathol. 2020 Mar 19. doi: 10.1007/s12022-020-09616-3. [Epub ahead of print]
PMID: 32193823
95. Metastatic malignant melanoma with neuroendocrine differentiation: a case report and review of the literature.
Juhlin CC, Zedenius J, Haglund F.
J Med Case Rep. 2020 Mar 31;14(1):44. doi: 10.1186/s13256-020-02367-z.
PMID: 32234068
96. Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion.
Juhlin CC, Asa SL, Jatta K, Naserhojati Rodsari H, Shabo I, Haglund F, Delahunt B, Samaratunga H, Egevad L, Höög A, Zedenius J.

- Head Neck Pathol.* 2020 Jun 9. doi: 10.1007/s12105-020-01187-3. Online ahead of print.
PMID: 32519264
97. Recurrent Amplification of the Osmotic Stress Transcription Factor NFAT5 in Adrenocortical Carcinoma.
Brown TC, Nicolson NG, Man J, Gibson CE, Stenman A, Juhlin CC, Korah R, Carling T.
J Endocr Soc. 2020 May 25;4(7):bvaa060. doi: 10.1210/jendso/bvaa060. eCollection 2020 Jul 1.
PMID: 32587934
98. Riedel Thyroiditis.
Zala A, Berhane T, Juhlin CC, Calissendorff J, Falhammar H.
J Clin Endocrinol Metab. 2020 Sep 1;105(9):dgaa468. doi: 10.1210/clinem/dgaa468.
PMID: 32687163
99. Macrofollicular Variant of Follicular Thyroid Carcinoma (MV-FTC) with a Somatic DICER1 Gene Mutation: Case Report and Review of the Literature.
Hellgren LS, Hysek M, Jatta K, Zedenius J, Juhlin CC.
Head Neck Pathol. 2020 Jul 25. doi: 10.1007/s12105-020-01208-1. Online ahead of print.
PMID: 32712880
100. PLEKHS1 Over-Expression is Associated with Metastases and Poor Outcomes in Papillary Thyroid Carcinoma.
Xing X, Mu N, Yuan X, Wang N, Juhlin CC, Strååt K, Larsson C, Xu D.
Cancers (Basel). 2020 Jul 31;12(8):E2133. doi: 10.3390/cancers12082133.
PMID: 32752127
101. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.
Juhlin CC, Zedenius J, Höög A.
Endocr Pathol. 2020 Aug 19. doi: 10.1007/s12022-020-09645-y. Online ahead of print.
PMID: 32813226
102. Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission.
Juhlin CC, Falhammar H, Kjellman M, Åhlén J, Welin S, Calissendorff J.
BMC Gastroenterol. 2020 Aug 27;20(1):290. doi: 10.1186/s12876-020-01433-6.
PMID: 32854635

Other publications (n = 3, reviews and articles in Swedish)

Parafibromin as a diagnostic instrument for parathyroid carcinoma -lone ranger or part of the posse?

Juhlin CC, Höög A.

Int J Endocrinol.; 324964, 2010. Epub 2010 Dec 12.

A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!

Juhlin CC.

Scand J Surg. 2019 May 26:1457496919850434. doi: 10.1177/1457496919850434.

[Epub ahead of print]

PMID: 31131695

[Endocrine tumours in Stockholm - increasing general incidence].

Juhlin CC, Stenman A, Zedenius J.

Läkartidningen. 2019 Mar 12;116. pii: FHM3. Swedish.

PMID: 31192414